Fintel reports that on December 27, 2024, Rodman & Renshaw downgraded their outlook for Viracta Therapeutics (NasdaqCM:VIRX) ...

A family's home was 'engulfed in fire' in London on Saturday, Dec. 14, after a second-hand e-bike exploded while three people were inside.

Rodman & Renshaw downgraded Viracta Therapeutics (VIRX) to Neutral from Buy with a price target of 25c, down from $3.50, after Viracta ...

Rodman & Renshaw initiated coverage of TuHURA Biosciences (HURA) with a Buy rating and $11 price target TuHURA is focused on developing ...

Town Manager Michael Renshaw proposed $182,725,337 million in operational spending for the coming fiscal year. This money ...

Adial Pharmaceuticals, Inc. (NASDAQ:ADIL – Get Free Report) was the target of a significant growth in short interest during the month of December. As of December 15th, there was short interest ...

Investors often prefer to invest in shares held by company insiders, as management is typically more aligned with the company’s success and shareholder interests. Currently, insiders own just 4.46% of ...

The incorrectly sized bay doors on the new Hatchville Fire Station will be replaced in about 18 weeks, and the general ...

When the going gets weird, Matt Renshaw turns pro. That's the word from the Brisbane Heat left-hander as he targets enhancing ...

Bloomington, IN- Jerry D. Renshaw, age 88, of Bloomington, and formerly of Spencer County, Indiana passed away peacefully Monday, November 25, 2024, at Brown County Health and Living Community in ...

Kyverna Therapeutics, Inc. (NASDAQ:KYTX – Get Free Report) has received an average rating of “Buy” from the nine brokerages that are currently covering the stock, Marketbeat.com reports. One research ...